IDWeek 2022 Notebook: Entasis Bolsters Case For SUL-DUR Antibiotic Combo
Entasis is hoping for a pathogen- rather than location-specific indication for sulbactam-durlobactam (SUL-DUR) in the US. Gilead’s Veklury remains a standard-of-care COVID-19 treatment. Summit claims further analysis of failed ridinilazole Phase III study shows recurrence advantage versus vancomycin.
You may also be interested in...
Some products are still going strong, while others that once generated blockbuster revenues have faded away, as companies develop next-generation antivirals and vaccines.
As expected, the COVID-19 drug’s sales fell significantly, though it remains in frequent use among hospitalized patients. Meanwhile, oncology drug sales broke the half billion-dollar mark.
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.